



9 September 2024

**ASX ANNOUNCEMENT (ASX:CBL)**

## **Control Bionics Expands Global Reach with Exclusive UK and Ireland Distribution Agreement**

Control Bionics Limited (ASX: CBL) is pleased to announce it has entered into an exclusive distribution agreement with Smart Box Ltd, the leading provider of assistive technology in the UK, for the sale of its innovative NeuroNode® device into the United Kingdom and Ireland.

This strategic partnership allows Control Bionics to expand the availability of its groundbreaking NeuroNode® technology to individuals with conditions such as Motor Neurone Disease (MND), cerebral palsy, and other neurological disorders that impair communication and motor function.

### **Highlights of the Agreement:**

- Exclusive distribution of NeuroNode® by Smart Box in the UK and Ireland.
- Access to Smart Box's established network of healthcare professionals and end-users.
- Strengthening Control Bionics' presence in the European market.

The material terms of the agreement are as follows.

- Smart Box UK is the exclusive distributor of the NeuroNode® (and its associated Controller App) for the UK and Ireland.
- The contract has an initial term of 2 years with no conditions precedent.
- Smart Box's minimum order quantities are 10 units with the pricing set out in the distribution agreement and 30 days payment terms.
- Either party may terminate the agreement giving 6 months' notice.

Whilst the commercial terms of this agreement remain confidential, this is clear demonstration of Control Bionics' previously disclosed strategy to rapidly grow its 'NeuroNode® Only' business. In the UK and Ireland more than 1,200 people are diagnosed with MND each year, with up to 2,000 being diagnosed with Cerebral Palsy each year in these countries. These two conditions typically make up about 50% of Control Bionics' customer base in Australia and the US.

The European market is a well established and well-funded market for Assistive Technology and the business is confident that this is the first of a number of agreements Control Bionics expects to sign for distribution of the NeuroNode® into Europe.

Jeremy Steele, CEO of Control Bionics, commented: *"We are thrilled to partner with Smart Box to bring NeuroNode® to the UK and Irish market. This exclusive agreement marks an exciting step in our mission to empower people with severe disabilities to communicate and regain control of their lives through innovative technology."*

Steele added, *"The NeuroNode® has already been paired with hundreds of Smart Box devices and devices with Smart Box software around the world. We're excited to extend this successful relationship to the UK and Ireland for the first time and look forward to building on this strong foundation to enhance the lives of users across these countries."*

Steele continued, *"By leveraging Smart Box's expertise and established network, we are confident that this partnership will accelerate the adoption of NeuroNode® across the UK and Ireland and improve the quality of life for countless individuals with speech and motor impairments."*

This announcement has been authorised for release by the CEO of Control Bionics, Jeremy Steele.

#### **About Control Bionics:**

Control Bionics is a medical device company assisting patients whose ability to communicate verbally or via text and social media is compromised by illnesses such as Motor Neurone Disease (MND) and Amyotrophic Lateral Sclerosis (ALS). Our core patented NeuroNode technology is a wireless wearable device that detects minute signals sent from the brain to any skeletal muscle and is captured as EMG (Electromyography) output. This output is then sent wirelessly via the NeuroNode to a personal computer, enabling speech and other computer controlled functions like email and texting. Our technology is integrated with eye gaze technology whereby the eye gaze enables a cursor to be moved about a computer screen, driven much like a mouse, and the NeuroNode acts as like the mouse button. Control Bionics is the only such product to harness three modalities – touch, eye and NeuroNode control – which combined yield unique benefits in terms of the ability of patients to express themselves with significantly faster speed and less fatigue.

Control Bionics recently extended its offering to mobility with the launch of DROVE – the autonomous wheelchair module. DROVE allows powered users the independence to operate their wheelchairs in their own homes for the first time. DROVE recently got approved by the TGA as a Class I medical device.

Control Bionics is currently commercialising its most recent advancement in its technology, the NeuroStrip®. This wearable, miniaturised EMG device provides the business with the opportunity to enter new markets such as health diagnostics, sports performance and rehabilitation to name only a few potential markets.

Control Bionics operates in North America, Australia, Singapore and Japan.

## **Investors and Media**

Jeremy Steele – CEO and Managing Director  
[jsteele@controlbionics.com](mailto:jsteele@controlbionics.com)

Brett Crowley - Company Secretary  
[brettcrowley@controlbionics.com](mailto:brettcrowley@controlbionics.com)

### **Investor Relations:**

Joe Durak  
Executive Director & Founder  
Lynx Advisors  
[joe@lynxadvisors.com.au](mailto:joe@lynxadvisors.com.au)  
+61 414 465 582

Control Bionics Limited  
Registered Office: Level 4, 11-13 Pearson St, Cremorne, Victoria 3121, Australia  
T: +61 3 9897 3576  
W: [www.controlbionics.com](http://www.controlbionics.com)  
ABN: 45 115 465 462